Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
Oosterhaven JAF, Spekhorst LS, Zhang J, Voorberg AN, Romeijn GLE, Boesjes CM, de Graaf M, de Bruin-Weller MS, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: schuttelaar mla. J Dermatolog Treat. 2022 Jun;33(4):1986-1989. doi: 10.1080/09546634.2021.1937485. Epub 2021 Jun 21. J Dermatolog Treat. 2022. PMID: 34151695
Presenteeism in a Dutch hand eczema population-a cross-sectional survey.
Oosterhaven JAF, Flach PA, Bültmann U, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: schuttelaar mla. Contact Dermatitis. 2018 Jul;79(1):10-19. doi: 10.1111/cod.12993. Epub 2018 Apr 1. Contact Dermatitis. 2018. PMID: 29607512 Free PMC article.
Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema.
Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: schuttelaar mla. JAMA Dermatol. 2018 Aug 1;154(8):969-970. doi: 10.1001/jamadermatol.2018.2027. JAMA Dermatol. 2018. PMID: 29971331 No abstract available.
European Surveillance System on Contact Allergies (ESSCA): Contact allergies in relation to body sites in patients with allergic contact dermatitis.
Oosterhaven JAF, Uter W, Aberer W, Armario-Hita JC, Ballmer-Weber BK, Bauer A, Czarnecka-Operacz M, Elsner P, García-Gavín J, Giménez-Arnau AM, John SM, Kręcisz B, Mahler V, Rustemeyer T, Sadowska-Przytocka A, Sánchez-Pérez J, Simon D, Valiukevičienė S, Weisshaar E, Schuttelaar MLA; ESSCA Working Group. Oosterhaven JAF, et al. Among authors: schuttelaar mla. Contact Dermatitis. 2019 May;80(5):263-272. doi: 10.1111/cod.13192. Epub 2019 Jan 14. Contact Dermatitis. 2019. PMID: 30520058 Free PMC article.
Which outcomes have been measured in hand eczema trials? A systematic review.
Rönsch H, Apfelbacher C, Brans R, Matterne U, Molin S, Ofenloch R, Oosterhaven JAF, Schuttelaar MLA, Weisshaar E, Yew YW, Bauer A. Rönsch H, et al. Among authors: schuttelaar mla. Contact Dermatitis. 2019 Apr;80(4):201-207. doi: 10.1111/cod.13212. Epub 2019 Feb 22. Contact Dermatitis. 2019. PMID: 30632613
[Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN, Oosterhaven JAF, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Voorberg AN, et al. Among authors: schuttelaar mla. Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227. Ned Tijdschr Geneeskd. 2019. PMID: 30945835 Dutch.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: schuttelaar mla. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
190 results